TC BioPharm’s cell banks have been developed as a resource for clinical development of cost-effective, safe and efficacious therapeutic treatments and ultimately, the ability to treat more patients. These T cell banks provide TC BioPharm with core technology to develop a deep portfolio of next-generation CAR-T products directed against a wide variety of different infectious diseases such as SARS-CoV-2 and cancer types, both hematological and solid tumors. Our cell bank project is supported by funding from the European Union’s Horizon 2020 (H2020) Research and Innovation program via a €4million grant, the largest such EU award to any UK company for the development of a healthcare therapeutic product. Cellular material is collected and stored from healthy donors, providing a source for TC BioPharm to manufacture next-generation ‘off-the-shelf’ GDT cell therapies for future clinical product development.
Advantages of Using Allogeneic Cell Banks:
- Hundreds of patients can be treated from a single donor.
- Campaign manufacturing allows for lower costs and consequently increased patient access and decreased burden on healthcare systems.
- Donors are selected to ensure that the banked cells have the ideal drug properties for GDT cell-based products.
- Reproducible manufacturing allows for consistent safety and potency.
These cell banks allow us to develop better products to reach more patients.